The Excipient of the Future
Advances in manufacturing aren’t enough to overcome the challenge of poorly soluble APIs – we must also embrace novel approaches to excipients
Dieter Lubda | | Opinion
Oral administration remains the most convenient form of delivery for patients and healthcare providers, but the poor solubility and bioavailability of newer APIs have become major roadblocks for pharmaceutical development. It has been reported that up to 80 percent of new chemical entities under development today have poor solubility, resulting in limited oral bioavailability. Consequently, technologies that help companies overcome the inherent low solubility of many newly developed APIs have never been more important.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine